Gsk Share Discussion Threads

[philo124] 16/7/2016 21:14

£20, nice!

[riskvsreward] 16/7/2016 18:12

For once some analyst is talking some sense, as he is saying what I said two weeks ago (post 12925). LOL.


GlaxoSmithKline shares have further to go
Pharmaceutical giant GlaxoSmithKline (GSK) has been upgraded on the back of its improving yield.

Jefferies analyst Jeffrey Holford upgraded his recommendation from ‘hold’ to ‘buy’ and increased the target price from £16.50 to £20.00. The shares fell 1.1% to £16.48 yesterday.

‘GSK’s 4.9% dividend yield is becoming increasingly well covered as its earnings rise, helped by recent foreign exchange movements, a strong performance from [HIV treatment subsidiary] ViiV and better than expected margin progression,’ he said.

‘We believe that fears of a dividend cut associated with the appointment of a new chief executive are overdone and that the macro environment (falling bond yields) could see the shares driven up to a 4% dividend yield.’

[toffeeman] 11/7/2016 16:57

Downtrend from 1998 to 2013 would be broken with a close above 1700 - bwtfdik

[toffeeman] 09/7/2016 17:59

Strange - I got my div yesterday

[tim 3] 09/7/2016 10:21

Yes this has been a real money cow ;)

Dividends,special dividends and a big share price boost to boot!

Luckily its my biggest holding.

If only all my investments had done this well!

[philo124] 09/7/2016 10:08

TM, good position to be in, well done.

[badtime] 09/7/2016 10:02

I can look after it for you :)

[tradermichael] 09/7/2016 09:27

Well, I have another massive GSK dividend payment coming next week. I usually enjoy re-investing it by purchasing more GSK shares, but this time around, after the recent climb, I'm not so sure. Maybe I'll hold it and wait for a possible drop at the next xd point (11 Aug?), and then buy.

[salpara111] 08/7/2016 12:38

well that is me out for 1650.
Entered at 1400 plus the divis makes it one of my best trades of the last year!
The £ seems to have stabilised Vs $ so not much more arbitrage to play there.

[tradermichael] 08/7/2016 10:26

After months of work under the radar, GlaxoSmithKline committed to entering the Zika R&D field, announcing on Thursday that it’s pairing with the National Institutes of Health in a project based at its new vaccine research hub in Rockville, MD.

[mr woodentop] 06/7/2016 14:10

I topped up yesterday - my thinking being although it costs more for us here in the UK to buy shares GSK ADR's are now cheaper to buy in US. Combined with pound weakness will increase the likelihood of a takeover bid

[tradermichael] 06/7/2016 11:26

Why? Do you think it has much further to go in the short term (from the falling pound?)?

[badtime] 06/7/2016 08:21

Bought back yesterday some of those I sold..to add to those I hold from £13's

[alphorn] 05/7/2016 22:32

A great currency hedge. When I have a moment I shall compare against my currency switches in the spot market - I expect will be close.

[tim 3] 05/7/2016 20:11

These are my biggest holding great to see them flying at last.

Talking heads on cnbc saying they see further sterling falls which should help.

Still tempted to take some of table as I think ftse 7k will be tough to break again and could see some profit taking infact I still think ftse 6k could be seen again in next year or sooner no doubt pulling these down with it and be nice to have some cash available to take advantage.

[philo124] 05/7/2016 18:49

Great, beats £17 yesterday.

[tradermichael] 05/7/2016 08:35

01/07/2016 – GlaxoSmithKline had its “Buy” rating reiterated by analysts at Citigroup. They now have a GBP 1800.00p price target on the stock.

[m_k_hubbert] 04/7/2016 17:28

As posted upthread I took 10% off the table and took similar action re IMB as recent strong performance had led to my being slightly overweight in these stocks. The issue to be faced when taking more substantial amounts off the table is 'where does one re-invest the proceeds'? The yields for holding cash are derisory and headed towards zero; furthermore those holding cash around time of referendum would have meant their missing out on the best days in the market since 2011 (assuming they were considering FTSE100 stocks with heavy international flavour). By contrast, if they were considering most of the FTSE250, or banks / financials, travel / leisure or housebuilders within the FTSE100 cash would have been the place to be. I'm not comfortable investing more than a modest amount in these sectors, even at bombed out levels, given that I can't tell at this stage whether a recovery has started or rises in latter part of last week were a 'dead cat bounce'. Based on what happened to building sector today it looks like the latter!

My view is that it will take 2 to 3 years before position re UK's place in the single market is resolved. Stocks such as GSK (and AZN, DGE, RDSB, ULVR etc) have a large portion of their earnings from outside the UK (and EU) thus offer more protection in event of additional problems in the EU. Their earnings are relatively safe and will benefit from further sterling depreciation (which some analysts are predicting). AZN and RDSB even declare dividends in USD which effectively means UK holders will soon receive an 11% dividend hike assuming declared dividends stay flat. On average these stocks, even after recent price rises, yield around 4.5%pa on average which amounts to a 14% return over 3 years assuming stock prices stay flat - there are worse places for one's money.

[ibug] 04/7/2016 08:55

GlaxoSmithKline plc (GSK)

Given New GBX 1,700 Price Target at Deutsche Bank AG

Posted by Carolyn Dwyer on Jul 4th, 2016 // No Comments

GlaxoSmithKline plc (LON:GSK) had its price target upped by Deutsche Bank AG from GBX 1,540 ($20.31) to GBX 1,700 ($22.42) in a research report issued to clients and investors on Monday. The brokerage presently has a “hold” rating on the stock. Deutsche Bank AG’s price target suggests a potential upside of 6.25% from the company’s previous close.

[tradermichael] 04/7/2016 08:32

LONDON--GlaxoSmithKline PLC (GSK.LN) said Thursday it has begun phase one of the clinical trial for a antibody that fights tumors.

The antibody is a co-stimulatory receptor that enhances T-cell responses and results in an increased anti-tumor response from the immune system, the pharmaceutical company said.

The study is a two-part clinical trial to evaluate the safety and properties of the antibody in patients with advanced or recurrent solid tumors, the company said. The study aims to identify a dose suitable for development, the company added.

[badtime] 01/7/2016 09:45

Half off the table at 1600

[tim 3] 01/7/2016 09:41

Also thinking of taking a bit "off the table"

Any views?

More concerned with wider market dropping and pulling gsk down with it.

Be very surprised if market as a whole does not have its traditional summer pullback on weak volume particularly from up here.

To be honest did not expect this rise and not sure its sustainable.